Julie A. Means‐Powell

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation

Joshua A. Bauer, A. Bapsi Chakravarthy, Jennifer M. Rosenbluth et al. · Clinical Cancer Research · 2010 · 187 citations · Full text

Medicine, Oncology, Pathology +17

A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer

Xia Li, E. Brian Welch, Lori R. Arlinghaus et al. · Physics in Medicine and Biology · 2011 · 74 citations

Medicine, Pharmacokinetics, Radiology +12

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

Igor Puzanov, Jeffrey A. Sosman, Armando Santoro et al. · Investigational New Drugs · 2014 · 57 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)

Julie A. Means‐Powell, Ingrid A. Mayer, Roohi Ismail‐Khan et al. · Clinical Breast Cancer · 2021 · 34 citations · Full text

Medicine, Oncology, Pharmacology +16